Influence of Erbanxiao solution on inhibiting angiogenesis in stasis toxin stagnation of non-small cell lung cancer

Journal of Traditional Chinese Medicine

Volumn 33, Issue 3, 2013, Pages 303-306

  Liu, Junbao ^a,b   Liu, Yanqing ^c  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c YANGZHOU UNIVERSITY   (China)

Author keywords

Angiogenesis; Carcinoma, Non small cell lung; Erbanxiao solution

Indexed keywords

ANGIOGENESIS INHIBITOR; CHINESE DRUG; ERBANXIAO; FIBROBLAST GROWTH FACTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER PATIENT; CHINESE MEDICINE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE;

EID: 84880466115     PISSN: 02552922     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0254-6272(13)60169-7     Document Type: Article

References (19)

1. Liu J X. Modern application of Traditional Chinese Medicine and research series. Volume fourteenth, oncology. Shanghai: Publishing company of Shanghai University of Traditional Chinese Medicine, 1996: 130.
2. Ye R G, Lu Z Y. Medicine. 6th Edition. Beijing: Beijing People's Medical Publishing House, 2004: 123.
3. Zheng X Y. Guiding principle of clinical research on new drugs of Traditional Chinese Medicine. Beijing: Publishing company of Chinese Medical Science and Technology, 2002: 378-385.
4. Mountain C F. Revisions in the international system for staging lung cancer. Chest 1997; 111(6): 1710-1717.
5. Obermair A, Speiser P, Reisenberger K, et al. Influence of intratumoral basic fibroblost growth factor concentration on survival in ovarian cancer patients. Cancer lett 1998; 130(1-2): 69-76.
6. Sun Y. Oncology. Beijing: People's Medical Publishing House, 2003: 994.
7. Wang K T. Chinese medicine clinical medicine series, treatment of the criterion. Shanghai: Publishing company of Shanghai science and Technology, 1602: 234.
8. Qian G S, Yu S. The latest data inspiration from the epidemiology lung cancer. Zhong Hua Jie He Yu Hu Xi Za Zhi 2012; 35(2): 86-89.
9. Zhou Y Q. Practical Oncology of Traditional Chinese Medicine integrated traditional Chinese and Western medicine therapy. Beijing: Beijing Publishing House of Chinese Ancient Books, 2005: 63.
10. Lin H S, Li S Q, Pu B K. Compound Traditional Chinese Medicine on patients with lung cancer tumor inhibition anti metastasis effect research. Zhong Guo Zhong Xi Yi Jie He Za Zhi 1998; 4(5): 277-279.
11. Huang W L. Tumor molecular targeted therapy. Beijing: Beijing people's Medical Publishing House, 2009: 1.
12. Zhang Q, Zhao Y Q, Xie X H, Niu X. Effects of Chinese herbs on tumor angiogenesis. Zhong Hua Zhong Yi Yao Za Zhi 2006; 21(4): 9.
13. Li J, Zhou H J. Two of dihydroartemisinin inhibits the expression of K562 on growth factor of cell vascular endothelial. Yao Xue Xue Bao 2005; 40(11): 104-108.
14. Feng G S. Experimental study of extract made from Bletilla inhibits angiogenesis mechanism. Zhong Hua Yi Xue Za Zhi 2003; 83(5): 412-416.
15. Gao Y, Wang J J, Xu Q, et al. The mechanism research of Rg3 of ginsenoside inhibition on tumor angiogenesis. Zhong Liu Fang Zhi Yan Jiu 2001; 28(3): 179-181.
16. Xu X Y, Yan P K, Chen G, Liao D F. Ligustrazine inhibited on mouse lung cancer angiogenesis and the expression of VEGF. Zhong Guo Yao Li Xue Tong Bao 2004; 20(2): 151-154.
17. Mo R G. The influence of norcantharidin on cultured human umbilical vein endothelial cell growth. Jie Po Ke Xue Jin Zhan 1999; 5(4): 370-371.
18. Lu F, Qiao L, Wan J P, et al. gastrointestinal tumor and peripheral blood of patients with SS, TNF-a, IL-6 and the clinical significance of detection of Sll-2R. Di Si Jun Yi Da Xue Xue Bao 2005; 26(19): 1795-1796.
19. Li J Q, Xia Y. The exploration of action of Traditional Chinese Medicine induced interferon. Shanghai Zhong Yi Yao Za Zhi 1993; 27(1): 34.